Unique ID issued by UMIN | UMIN000049727 |
---|---|
Receipt number | R000056642 |
Scientific Title | Xocova tablets drug use-results survey |
Date of disclosure of the study information | 2022/12/08 |
Last modified on | 2022/12/08 13:16:57 |
Xocova tablets drug use-results survey
Xocova tablets drug use-results survey
Xocova tablets drug use-results survey
Xocova tablets drug use-results survey
Japan |
SARS-CoV-2 infection
Infectious disease |
Others
NO
To assess safety and clinical outcome of Xocova tablets under clinical practice.
Safety,Efficacy
Others
Others
Not applicable
Safety
Incidence of adverse drug reactions
Clinical outcome
Time to resolution of COVID-19 symptoms in SARS-CoV-2 infected patients
The number and rate of hospitalization for COVID-19 or death from any cause through day 28
Observational
12 | years-old | <= |
Not applicable |
Male and Female
SARS-CoV-2 infected patient who has not been treated with Xocova tablets and provides an informed consent in written for data collection and analysis
NA
3000
1st name | Masako |
Middle name | |
Last name | Kaneto |
Shionogi & Co., Ltd.
Pharmacovigilance Department
541-0042
3-13, Imabashi 3-Chome, Chuo-ku, Osaka 541-0042, Japan
+81-6-6209-6974
masako.kaneto@shionogi.co.jp
1st name | Satoru |
Middle name | |
Last name | Takashima |
Shionogi & Co., Ltd.
Pharmacovigilance Department
541-0042
3-13, Imabashi 3-Chome, Chuo-ku, Osaka 541-0042, Japan
+81-6-6209-6929
satoru.takashima@shionogi.co.jp
Shionogi & Co., Ltd.
Shionogi & Co., Ltd.
Profit organization
NA
NA
NA
NA
NO
2022 | Year | 12 | Month | 08 | Day |
Unpublished
Preinitiation
2022 | Year | 11 | Month | 22 | Day |
2022 | Year | 12 | Month | 08 | Day |
2023 | Year | 12 | Month | 31 | Day |
NA
2022 | Year | 12 | Month | 08 | Day |
2022 | Year | 12 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056642